ArriVent BioPharma (AVBP) Operating Expenses (2023 - 2026)

ArriVent BioPharma has disclosed Operating Expenses across 4 years of filings, most recently posting $46.1 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $46.1 million, down 30.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $156.9 million (up 11.73% YoY), and the FY2025 annual result was $177.5 million, up 88.25% from the prior year.
• Operating Expenses came in at $46.1 million for Q1 2026 at ArriVent BioPharma, up from $38.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $66.8 million in Q1 2025 to a low of $12.2 million in Q1 2023.
• The 4-year median for Operating Expenses is $24.2 million (2024), against an average of $30.2 million.
• Across the five-year window, Operating Expenses surged 222.98% in 2025 and plunged 30.94% in 2026, its largest moves.
• ArriVent BioPharma's Operating Expenses stood at $23.1 million in 2023, then gained by 2.54% to $23.7 million in 2024, then soared by 63.78% to $38.8 million in 2025, then climbed by 18.77% to $46.1 million in 2026.
• The last three Operating Expenses figures came in at $46.1 million (Q1 2026), $38.8 million (Q4 2025), and $38.3 million (Q3 2025), per Business Quant data.